



TITLE: Cystoscopy for the Diagnosis of Patients with Urological Issues: Guidelines

DATE: 27 June 2014

RESEARCH QUESTION

What are the evidence-based guidelines regarding the use of cystoscopy for the diagnosis of patients with urological issues?

KEY MESSAGE

One systematic review and six evidence-based guidelines were identified regarding the use of cystoscopy for the diagnosis of patients with urological issues.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 6), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, and Guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and June 22, 2014. Internet links were provided, where available.

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by evidence-based guidelines.

One systematic review and six evidence-based guidelines were identified regarding the use of cystoscopy for the diagnosis of patients with urological issues. No relevant health technology assessments or meta-analyses were identified.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. **This report may be used for the purposes of research or private study only.** It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

Additional references of potential interest are provided in the appendix.

Health Technology Assessments

No literature available.

Systematic Reviews and Meta-analyses

1. Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. *Eur Urol.* 2013 Oct;64(4):624-38.
[PubMed: PM23906669](#)

Guidelines and Recommendations

2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. *Eur Urol.* 2013 Oct;64(4):639-53.
[PubMed: PM23827737](#)
3. Kapoor A, Allard CB, Black P, Kassouf W, Morash C, Rendon R. Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. *Canadian Urological Association Journal [Internet].* 2013 Sep-Oct [cited 2014 Jun 26]; 7(9-10): 306-311. Available from:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854466/pdf/cuaj-9-10-306.pdf>
See: Surveillance Protocol and table 1, page 308-310
4. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, et al. Guidelines on urothelial carcinomas of the upper urinary tract [Internet]. Arnhem (The Netherlands): European Association of Urology (EAU); 2013. [cited 2014 Jun 26]. Available from:
http://www.uroweb.org/gls/pdf/06_UTUC_LR.pdf
Summary available from:
<http://www.guideline.gov/content.aspx?id=45315&search=cystoscopy>
See: Table 2: Guidelines for the diagnosis of UTUC, page 7
Table 5: Guidelines for follow-up of UTUC patients after initial treatment, page 12
5. Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. *J Urol.* 2012 Dec;188(6 Suppl):2473-81.
[PubMed: PM23098784](#)
6. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, FitzGerald MP, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Linthicum (MD): American Urological Association (AUA); 2011. Summary available from:
<http://www.guideline.gov/content.aspx?id=32489&search=cystoscopy>
See: Diagnosis #3

7. Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. *Can Urol Assoc J* [Internet]. Oct 2011 [cited 2014 Jun 26]; 5(5): 316–322. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202002/>
See: Text box 1. Summary of Recommendations, 3a Investigation of recurrent uncomplicated UTI

PREPARED BY:

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439

www.cadth.ca

APPENDIX – FURTHER INFORMATION:

Non-Randomized Study

8. Holmang S, Strock V. Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? *Eur Urol.* 2012 Mar;61(3):503-7.
[PubMed: PM22119022](#)

Guidelines and Recommendations

Expert Consensus

9. Malmstrom PU, Grabe M, Haug ES, Hellstrom P, Hermann GG, Mogensen K, et al. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. *Scand J Urol Nephrol.* 2012 Apr;46(2):108-16.
[PubMed: PM22087730](#)

Initial Assessment

10. Urinary incontinence: The management of urinary incontinence in women [Internet]. Manchester: National Institute for Health and Clinical Excellence; 2013. [cited 2014 Jun 26]. Available from:
<http://www.nice.org.uk/nicemedia/live/14271/65143/65143.pdf>
See: *Cystoscopy 1.1.24, page 13*

Uncertain Methodology

11. Arnold J, McLeod N, Thani-Gasalam R, Rashid P. Overactive bladder syndrome Management and treatment options [Internet]. East Melbourne: The Royal Australian College of General Practitioners; 2011. [cited 2014 Jun 26]. Available from:
<http://www.racgp.org.au/download/Documents/AFP/2012/November/201211arnold.pdf>
See: *Diagnosis and Table 2. Investigations for overactive bladder syndrome, page 879*
12. Bellmunt J, Orsola A, Maldonado X, Kataja V, ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* [Internet]. 2010 May [cited 2014 Jun 26];21 Suppl 5:v134-v136. Available from:
http://annonc.oxfordjournals.org/content/21/suppl_5/v134.long
13. Hanno P, Lin A, Nordling J, Nyberg L, van OA, Ueda T, et al. Bladder Pain Syndrome Committee of the International Consultation on Incontinence. *Neurourol Urodyn.* 2010;29(1):191-8.
[PubMed: PM20025029](#)

Review Articles

14. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS, Recent advances in the diagnosis and treatment of bladder cancer [Internet]. *BMC Med.* 2013 [cited 2014 Jun 26];11:13. Available from: <http://pubmedcentralcanada.ca/pmcc/articles/PMC3566975/>

15. Fall M, Peeker R. Methods and incentives for the early diagnosis of bladder pain syndrome/interstitial cystitis. *Expert Opin Med Diagn.* 2013 Jan;7(1):17-24.
[PubMed: PM23530841](#)
16. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. *Eur Urol.* 2013 Jan;63(1):4-15.
[PubMed: PM23083902](#)
17. Faba OR, Palou J, Breda A, Villavicencio H. High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. *World J Urol.* 2012 Dec;30(6):833-40.
[PubMed: PM23070534](#)
18. Quillin RB, Erickson DR. Practical use of the new American Urological Association interstitial cystitis guidelines. *Curr Urol Rep.* 2012 Oct;13(5):394-401.
[PubMed: PM22828913](#)
19. Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. *Eur Urol.* 2012 Aug;62(2):290-302.
[PubMed: PM22609313](#)
20. Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmstrom PU, Riedl C, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. *Eur Urol.* 2010 Apr;57(4):607-14.
[PubMed: PM20116164](#)

Additional References

21. Fradet Y. Screening for bladder cancer: the best opportunity to reduce mortality. *Can Urol Assoc J [Internet].* 2009;3(Suppl4):S180-3. Available from:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792451/>